In vitro and in vivo evaluation of CYP1a interaction potential of terminalia arjuna bark

Indian Journal of Pharmaceutical Sciences

Volumn 76, Issue 2, 2014, Pages 138-147

  Varghese, Alice ^a   Pandita, Nancy ^a   Gaud, R S ^a  

^a SVKM s Narsee Monjee Institute of Management Studies   (India)

Author keywords

CYP1A interaction; drug herb interaction; liver microsomes; Terminalia arjuna

Indexed keywords

ARJUNGENIN; ARJUNIC ACID; CYTOCHROME P450 1A; ENZYME INHIBITOR; PHENACETIN; PLANT EXTRACT; TERMINALIA ARJUNA EXTRACT; UNCLASSIFIED DRUG;

ALCOHOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BARK; CONTROL GROUP; DRUG HALF LIFE; ENZYME ASSAY; ENZYME INHIBITION; EXTRACT; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; RAT; TERMINALIA ARJUNA;

EID: 84899695537     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jain S, Yadav PP, Gill V, Vasudeva N, Singla N. Terminalia arjuna a sacred medicinal plant: Phytochemical and pharmacological profile. Phytochem Rev 2009;8:491-502.
2. Nadkarni AK. Terminalia Arjuna. Indian Mater Med 1976;1:1198-202.
3. Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Boca Raton, FL: CRC Press; 1990. p. 319-20.
4. Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala-A Rasayana from Ayurveda. J Ethnopharmacol 2011;133:120-5.
5. Hu L, Xu W, Zhang X, Su J, Liu X, Li H, et al. In vitro and in vivo evaluations of Cytochrome P450 1A2 interactions with nuciferine. J Pharm Pharmacol 2010;62:658-62.
6. Guengerich PF. Cytochrome P450 Enzymes. Am Sci 1993;8i:440-7.
7. Subash CV, Chotten LJ, Madan MP, Ramesh BD. Microwave extraction and rapid isolation of arjunic acid from Terminalia arjuna (Roxb. ex DC.) stem bark and quantification of arjunic acid and arjunolic acid using HPLC-PDA technique. J Sep Sci 2012;35:1627-33.
8. Savai J, Varghese A, Pandita N. Lack of the cytochrome P450 3A interaction of methanolic extract of Withania somnifera, Withaferin A, Withanolide A and Withanoside IV. J Pharm Negat Results 2013;4:26-32.
9. Guidance for Industry-Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Clinical Pharmacology 2006. available at http://www. fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf [Last accessed on 2014 Feb 27].
10. Chmielewska A, Konieczna J, Plenis A, Lamparczyk H. Quantitative determination of pentoxifylline in human plasma. Acta Chromatogr 2006;16:70-9.
11. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). J Pharm Pharmacol 2005;61:1529-36.
12. Miroslaw M, Katarzyna ZS, Marta J, Monika M. In vivo effect of diallyl sulfide and cimetidine on phenacetin metabolism and bioavailability in rat. Acta Biochim Pol 2002;49:249-56.
13. Bharani A, Ganguly A, Bhargava K. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol 1995;49:191-9.
14. Maulik S, Talwar K. Therapeutic potential of terminalia Arjuna in cardiovascular disorders. Am J Cardiovasc Drugs 2012;12:157-63.
15. Maulik S, Katiyar K. Terminalia Arjuna in cardiovascular diseases: Making the transition from traditional to modern medicine in India. Curr Pharma Biotechnol 2010;11:855-60.
16. Takahashi S, Tanaka H, Hano Y, Nomura T, Shigenobu K. Hypotensive effects in rats of hydrophilic extract from Terminalia arjuna containing tannin-related compounds. Phytother Res 1997;11:424-7.
17. Dwivedi S, Somani P, Chansouria J, Udupa K. Cardioprotective effects of certain indigenous drugs in myocardial ischemia in rabbits. Indian J Exp Biol 1988;26:969-75.
18. Pawar R, Bhutani KK. Effect of oleanane triterpenoids from Terminalia Arjuna: A cardioprotective drug on the process of respiratory oxyburst. Phytomedicine 2005;12:391-3.
19. Sumitra M, Manikandan P, Kumar A. Experimental myocardial necrosis in rats: Role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol Cell Biochem 2001;224:135-42.
20. Khanna K, Chander C, Kapoor K. Terminalia Arjuna: An Ayurvedic cardiotonic regulates lipid metabolism in hyperlipidemic rats. Phytother Res 1996;10:663-6.
21. Subramaniam S, Ramachandran S, Uthrapathi S, Dubey G. Antihyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX-407 induced hyperlipidemia. Indian J Exp Biol 2011;49:282-8.
22. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med 2005;165:281-6.
23. Fasinu P, Bouic P, Rosenkranz B. A overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol 2012;3:1-19.
24. Badal S, Williams SA, Huang G, Francis S, Vendantam P, Dunbar O, et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumier. Fitoterapia 2011;82:230-6.
25. Nelson S, Trager W. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome p450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos 2003;31:1481-97.
26. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010;55:515-25.
27. Marcella M, Geny G, Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875-94.
28. Mandlekar V, Rose V. Cornelius U. Sleczka B, Caporuscio C, Wang J, et al. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica 2006;37:923-42.